Sectors
AVTX
Avalo Therapeutics, Inc.
18.41
1 x 18.28
7 x 18.40
bid
ask
-
0.41
2.21%
10:05 AM
timesize
| Ytd | 1.35% | |
| 1y | 186.68% |
18.19
day range
18.96
6.21
52 week range
24.27
| Open | 18.54 | Prev Close | 18.82 | Low | 18.19 | High | 18.96 | Mkt Cap | 212.56M |
| Vol | 40.46K | Avg Vol | 2.00M | EPS | -5.46 | P/E | -3.45 | Forward P/E | -6.95 |
| Beta | 0.78 | Short Ratio | 5.86 | Inst. Own | 75.28% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 17.02 | 200-d Avg | 16.32 | 1yr Est | 44.69 |
| Income Statement | |||
| Operating Expenses | 20.90M | ||
| Research and Development Expense | 14.05M | ||
| Selling, General and Administrative Expense | 6.85M | ||
| Operating Income | -20.90M | ||
| Income Tax Expense | 12.00K | ||
| Net Income | -19.63M | ||
| Net Income Common Stock | -19.63M | ||
| Net Income Common Stock (USD) | -19.63M | ||
| Consolidated Income | -19.63M | ||
| Earnings per Basic Share | -0.98 | ||
| Earnings per Basic Share (USD) | -0.98 | ||
| Earnings per Diluted Share | -0.98 | ||
| Earning Before Interest & Taxes (EBIT) | -19.62M | ||
| Earning Before Interest & Taxes (USD) | -19.62M | ||
| Weighted Average Shares | 20.11M | ||
| Weighted Average Shares Diluted | 20.11M | ||
| Balance Sheet | |||
| Cash and Equivalents | 25.14M | ||
| Cash and Equivalents (USD) | 25.14M | ||
| Investments | 57.19M | ||
| Investments Current | 57.01M | ||
| Investments Non-Current | 183.00K | ||
| Current Assets | 88.83M | ||
| Property, Plant & Equipment Net | 375.00K | ||
| Total Assets | 99.89M | ||
| Current Liabilities | 11.60M | ||
| Total Liabilities | 31.57M | ||
| Accumulated Retained Earnings (Deficit) | -468.15M | ||
| Accumulated Other Comprehensive Income | -6.00K | ||
| Shareholders Equity | 68.32M | ||
| Shareholders Equity (USD) | 68.32M | ||
| Assets Non-Current | 11.06M | ||
| Goodwill and Intangible Assets | 10.50M | ||
| Liabilities Non-Current | 19.97M | ||
| Trade and Non-Trade Payables | 356.00K | ||
| Tax Liabilities | 446.00K | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 17.00K | ||
| Net Cash Flow from Financing | 1.40M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 9.21M | ||
| Issuance (Purchase) of Equity Shares | 2.18M | ||
| Net Cash Flow from Investing | 25.51M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 25.51M | ||
| Net Cash Flow from Operations | -17.69M | ||
| Share Based Compensation | 3.58M | ||